Latest-analyses-Vitrakvi-larotrectinib-reaffirm-powerful-efficacy-tolerability-profile-adult
In an updated analysis on the adult subset of non-central nervous system (CNS) / TRK fusion cancer patients from three larotrectinib clinical trials, a high overall response rate (ORR) of 67% with a median duration of response (mDoR) of 49.3 months was observed as well as an extended progression-free survival (PFS; median of 25.8 months) as assessed by investigators / Post hoc sub-analysis of investigator-assessed ORR, DoR and PFS of patients (n=218) show uniformly high ORRs in patients regardless of prior treatment or performance status; highest response rates observed in patients receiving first-line larotrectinib (81%) ...
Source: Bayer Company News - September 16, 2021 Category: Pharmaceuticals Source Type: news
Bayer-starts-Phase-III-clinical-development-program-OASIS-with-Elinzanetant
Elinzanetant is an innovative non-hormonal development compound investigated for the treatment of vasomotor symptoms during menopause (Source: Bayer Company News)
Source: Bayer Company News - August 31, 2021 Category: Pharmaceuticals Source Type: news
New-Data-Finerenone-protection-patients-chronic-kidney-disease-2-diabetes-cardiovascular-events
(Source: Bayer Company News)
Source: Bayer Company News - August 28, 2021 Category: Pharmaceuticals Source Type: news
Bayer-Strong-growth-guidance-upgrade
Group sales increase by 12.9 percent (Fx & portfolio adj.) to 10.854 billion euros – double-digit percentage growth (Fx & portfolio adj.) at all divisions / EBITDA before special items declines by 10.6 percent to 2.577 billion euros, burdened by currency effects of 153 million euros / Crop Science posts strong sales growth, earnings impacted by higher costs and currency effects / Pharmaceuticals reports significant recovery after COVID-19 effects in prior year / Consumer Health continues growth momentum / Core earnings per share rise by 1.3 percent to 1.61 euros / Net income at minus 2.335 billion euros, additional p...
Source: Bayer Company News - August 5, 2021 Category: Pharmaceuticals Source Type: news
Bayer-strengthens-drug-discovery-platform-through-acquisition-of-Vividion-Therapeutics
Acquisition strengthens Bayer’s drug discovery capabilities with cutting-edge chemoproteomics platform / Vividion’s unique approach identifies previously unknown binding pockets in undruggable targets to generate first-in-class novel compounds in indications of high unmet medical need / Vividion’s technology has already proven its applicability pre-clinically in oncology and immune-related diseases, with potential to expand into additional therapeutic areas / Vividion to operate autonomously and on an arm’s length basis / Purchase price of USD 1.5 billion upfront and up to USD 500 million in success...
Source: Bayer Company News - August 5, 2021 Category: Pharmaceuticals Source Type: news
Bayer-Provides-Update-on-Path-to-Closure-of-Roundup-Litigation
(Source: Bayer Company News)
Source: Bayer Company News - July 29, 2021 Category: Pharmaceuticals Source Type: news
Bayers-new-symptomatic-chronic-heart-failure-treatment-Verquvo-vericiguat-approved-in-EU
Approved for adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous therapy / Studied in a population with a high risk of cardiovascular death or heart failure hospitalization / The sGC-stimulator Verquvo provides a specific approach to managing chronic heart failure following a decompensation event (Source: Bayer Company News)
Source: Bayer Company News - July 21, 2021 Category: Pharmaceuticals Source Type: news
US-FDA-approves-finerenone-treatment-patients-chronic-kidney-disease-associated-2-diabetes
Finerenone is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and cardiovascular outcomes in patients with chronic kidney disease associated with type 2 diabetes / Despite guideline-directed therapies, many patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) still progress to loss of kidney function and are at high risk for cardiovascular events / By blocking MR overactivation, a key driver of CKD progression, finerenone works on a pathway largely unaddressed by existing treatments for CKD in T2D (Source: Bayer Company News)
Source: Bayer Company News - July 9, 2021 Category: Pharmaceuticals Source Type: news
Vericiguat-approved-in-Japan-to-treat-patients-with-chronic-heart-failure
Heart failure affects approximately 1.2 million people in Japan (Source: Bayer Company News)
Source: Bayer Company News - June 23, 2021 Category: Pharmaceuticals Source Type: news
Bayer-submits-regulatory-applications-oncology-treatment-combination-copanlisib-rituximab-US-EU
In the US, Bayer has filed for relapsed indolent B-cell non-Hodgkin’s lymphoma (B-iNHL) / In the EU, Bayer has filed for relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted / Filings based on results from Phase III trial CHRONOS-3 showing a significant improvement in the primary endpoint of progression-free survival for the combination of copanlisib and rituximab in patients with relapsed iNHL (Source: Bayer Company News)
Source: Bayer Company News - June 21, 2021 Category: Pharmaceuticals Source Type: news
Bayer-to-advance-two-first-of-its-kind-cell-and-gene-therapies-for-Parkinsons-disease
Parkinson’s disease is most common neurodegenerative movement disorder / It impacts more than 10 million people worldwide/ No function-restoring therapy is currently available / Bayer is pursuing a two-pronged approach to deliver transformative therapies with one cell and one gene therapy candidate in clinical trials (Source: Bayer Company News)
Source: Bayer Company News - June 8, 2021 Category: Pharmaceuticals Source Type: news
Bayer-acquires-Noria-and-PSMA-Therapeutics-to-expand-portfolio-in-prostate-cancer
Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer (Source: Bayer Company News)
Source: Bayer Company News - June 3, 2021 Category: Pharmaceuticals Source Type: news
Bayer-announces-five-point-plan-to-effectively-address-potential-future-Roundup-claims
(Source: Bayer Company News)
Source: Bayer Company News - May 27, 2021 Category: Pharmaceuticals Source Type: news
Precision-oncology-treatment-Larotrectinib-submitted-for-marketing-authorization-in-China
(Source: Bayer Company News)
Source: Bayer Company News - May 25, 2021 Category: Pharmaceuticals Source Type: news
Positive-CHMP-opinion-for-Bayers-new-symptomatic-chronic-heart-failure-treatment-vericiguat
Vericiguat is being considered for adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy / Vericiguat was studied in a population with a high risk of cardiovascular death or heart failure hospitalization / European Commission decision is expected in the coming months (Source: Bayer Company News)
Source: Bayer Company News - May 21, 2021 Category: Pharmaceuticals Source Type: news
